Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus's subsidiary, Optival Health Solutions Private Limited, received suspension orders for the Drug License of four stores in Maharashtra (Sharda Colony, Shankar Chowk Sindhi Colony, Ingale Square Civil Lines, and Jagnade Chowk Amgaon Gondia). Each store's license has been suspended for five days under Rule 65 of the Drugs and Cosmetics Act, 1940, by the Asst. Commissioner & Licensing Authority, Food & Drug Administration, Maharashtra. The orders were received on April 13, 2025. The estimated revenue loss per store ranges from about Rs 1.63 lakhs to Rs 1.98 lakhs, totaling roughly Rs 7 lakhs across all four stores.
The financial impact is negligible (under Rs 7 lakhs total) and limited to a 5-day suspension per store, so this is unlikely to have any material effect on the company's overall operations or stock price.